These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25596737)

  • 1. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells.
    Cusimano A; Puleio R; D'Alessandro N; Loria GR; McCubrey JA; Montalto G; Cervello M
    Oncotarget; 2015 Jan; 6(3):1707-22. PubMed ID: 25596737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic value of SC66 in human renal cell carcinoma cells.
    Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
    Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
    Wu YH; Huang YF; Chen CC; Chou CY
    Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/β-catenin pathway.
    Chen W; Zhao S; Yu W; Rao T; Ruan Y; Zhu S; Xia Y; Song H; Cheng F
    J Cell Mol Med; 2021 Nov; 25(22):10684-10697. PubMed ID: 34687144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
    Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
    Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma.
    Liao S; Wang Q; Chen S; Huang Q; Zhou L; Liu H; He S; Zhou Z
    J Transl Med; 2024 Aug; 22(1):792. PubMed ID: 39198815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
    Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
    Oncotarget; 2014 May; 5(9):2853-63. PubMed ID: 24797310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice.
    Zhang ZJ; Yang YK; Wu WZ
    J Transl Med; 2014 Feb; 12():57. PubMed ID: 24581171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.
    Liao YJ; Bai HY; Li ZH; Zou J; Chen JW; Zheng F; Zhang JX; Mai SJ; Zeng MS; Sun HD; Pu JX; Xie D
    Cell Death Dis; 2014 Mar; 5(3):e1137. PubMed ID: 24651440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
    Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
    Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
    Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
    Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
    Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
    Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.